HEADER TRANSCRIPTION/AGONIST 29-NOV-17 6BR2 TITLE STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL ISOQUINOLINE INVERSE TITLE 2 AGONIST. COMPND MOL_ID: 1; COMPND 2 MOLECULE: NUCLEAR RECEPTOR ROR-GAMMA; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: NUCLEAR RECEPTOR RZR-GAMMA,NUCLEAR RECEPTOR SUBFAMILY 1 COMPND 5 GROUP F MEMBER 3,RAR-RELATED ORPHAN RECEPTOR C,RETINOID-RELATED COMPND 6 ORPHAN RECEPTOR-GAMMA; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: RORC, NR1F3, RORG, RZRG; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS NUCLEAR HORMONE RECEPTOR, INVERSE AGONIST, COMPLEX, TRANSCRIPTION- KEYWDS 2 AGONIST COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR R.J.SKENE,I.HOFFMAN REVDAT 3 13-MAR-24 6BR2 1 REMARK REVDAT 2 25-APR-18 6BR2 1 JRNL REVDAT 1 21-MAR-18 6BR2 0 JRNL AUTH M.KONO,A.OCHIDA,T.ODA,T.IMADA,Y.BANNO,N.TAYA,S.MASADA, JRNL AUTH 2 T.KAWAMOTO,K.YONEMORI,Y.NARA,Y.FUKASE,T.YUKAWA,H.TOKUHARA, JRNL AUTH 3 R.SKENE,B.C.SANG,I.D.HOFFMAN,G.P.SNELL,K.UGA,A.SHIBATA, JRNL AUTH 4 K.IGAKI,Y.NAKAMURA,H.NAKAGAWA,N.TSUCHIMORI,M.YAMASAKI, JRNL AUTH 5 J.SHIRAI,S.YAMAMOTO JRNL TITL DISCOVERY OF [ CIS-3-({(5 JRNL TITL 2 R)-5-[(7-FLUORO-1,1-DIMETHYL-2,3-DIHYDRO-1 JRNL TITL 3 H-INDEN-5-YL)CARBAMOYL]-2-METHOXY-7,8-DIHYDRO-1, JRNL TITL 4 6-NAPHTHYRIDIN-6(5 H)-YL}CARBONYL)CYCLOBUTYL]ACETIC ACID JRNL TITL 5 (TAK-828F) AS A POTENT, SELECTIVE, AND ORALLY AVAILABLE JRNL TITL 6 NOVEL RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR GAMMA T JRNL TITL 7 INVERSE AGONIST. JRNL REF J. MED. CHEM. V. 61 2973 2018 JRNL REFN ISSN 1520-4804 JRNL PMID 29510038 JRNL DOI 10.1021/ACS.JMEDCHEM.8B00061 REMARK 2 REMARK 2 RESOLUTION. 3.18 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 3.18 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 43.23 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 3 NUMBER OF REFLECTIONS : 11396 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.178 REMARK 3 R VALUE (WORKING SET) : 0.175 REMARK 3 FREE R VALUE : 0.227 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.900 REMARK 3 FREE R VALUE TEST SET COUNT : 589 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3475 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 86 REMARK 3 SOLVENT ATOMS : 18 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 107.6 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.60000 REMARK 3 B22 (A**2) : 0.60000 REMARK 3 B33 (A**2) : -1.96000 REMARK 3 B12 (A**2) : 0.30000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): NULL REMARK 3 ESU BASED ON FREE R VALUE (A): 0.411 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.323 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 43.838 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 DISTANCE RESTRAINTS. RMS SIGMA REMARK 3 BOND LENGTH (A) : NULL ; NULL REMARK 3 ANGLE DISTANCE (A) : NULL ; NULL REMARK 3 INTRAPLANAR 1-4 DISTANCE (A) : NULL ; NULL REMARK 3 H-BOND OR METAL COORDINATION (A) : NULL ; NULL REMARK 3 REMARK 3 PLANE RESTRAINT (A) : NULL ; NULL REMARK 3 CHIRAL-CENTER RESTRAINT (A**3) : NULL ; NULL REMARK 3 REMARK 3 NON-BONDED CONTACT RESTRAINTS. REMARK 3 SINGLE TORSION (A) : NULL ; NULL REMARK 3 MULTIPLE TORSION (A) : NULL ; NULL REMARK 3 H-BOND (X...Y) (A) : NULL ; NULL REMARK 3 H-BOND (X-H...Y) (A) : NULL ; NULL REMARK 3 REMARK 3 CONFORMATIONAL TORSION ANGLE RESTRAINTS. REMARK 3 SPECIFIED (DEGREES) : NULL ; NULL REMARK 3 PLANAR (DEGREES) : NULL ; NULL REMARK 3 STAGGERED (DEGREES) : NULL ; NULL REMARK 3 TRANSVERSE (DEGREES) : NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: U VALUES : WITH TLS ADDED REMARK 4 REMARK 4 6BR2 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 30-NOV-17. REMARK 100 THE DEPOSITION ID IS D_1000231307. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 29-JUN-13 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ALS REMARK 200 BEAMLINE : 5.0.3 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.97 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 315R REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 12017 REMARK 200 RESOLUTION RANGE HIGH (A) : 3.180 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 200 DATA REDUNDANCY : 4.700 REMARK 200 R MERGE (I) : 0.06100 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 11.9000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 3.18 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.23 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 4.80 REMARK 200 R MERGE FOR SHELL (I) : 0.94000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 65.94 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.61 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 2%MPD, 1.2M NAFORMATE, 0.1M HEPES 7.5, REMARK 280 VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 291K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 61 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+1/3 REMARK 290 3555 -X+Y,-X,Z+2/3 REMARK 290 4555 -X,-Y,Z+1/2 REMARK 290 5555 Y,-X+Y,Z+5/6 REMARK 290 6555 X-Y,X,Z+1/6 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 41.82800 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 83.65600 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 62.74200 REMARK 290 SMTRY1 5 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 5 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 104.57000 REMARK 290 SMTRY1 6 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 20.91400 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 SER B 477 REMARK 465 GLN B 478 REMARK 465 HIS B 479 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 SER A 266 -153.03 -108.28 REMARK 500 GLN A 286 -54.99 63.95 REMARK 500 GLU A 435 75.34 -101.53 REMARK 500 SER A 477 -73.77 -97.92 REMARK 500 GLN B 286 -56.82 67.13 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue MPD A 501 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue E3S A 502 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue MPD B 501 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue E3S B 502 DBREF 6BR2 A 265 479 UNP P51449 RORG_HUMAN 265 479 DBREF 6BR2 B 265 479 UNP P51449 RORG_HUMAN 265 479 SEQRES 1 A 215 ALA SER LEU THR GLU ILE GLU HIS LEU VAL GLN SER VAL SEQRES 2 A 215 CYS LYS SER TYR ARG GLU THR CYS GLN LEU ARG LEU GLU SEQRES 3 A 215 ASP LEU LEU ARG GLN ARG SER ASN ILE PHE SER ARG GLU SEQRES 4 A 215 GLU VAL THR GLY TYR GLN ARG LYS SER MET TRP GLU MET SEQRES 5 A 215 TRP GLU ARG CYS ALA HIS HIS LEU THR GLU ALA ILE GLN SEQRES 6 A 215 TYR VAL VAL GLU PHE ALA LYS ARG LEU SER GLY PHE MET SEQRES 7 A 215 GLU LEU CYS GLN ASN ASP GLN ILE VAL LEU LEU LYS ALA SEQRES 8 A 215 GLY ALA MET GLU VAL VAL LEU VAL ARG MET CYS ARG ALA SEQRES 9 A 215 TYR ASN ALA ASP ASN ARG THR VAL PHE PHE GLU GLY LYS SEQRES 10 A 215 TYR GLY GLY MET GLU LEU PHE ARG ALA LEU GLY CYS SER SEQRES 11 A 215 GLU LEU ILE SER SER ILE PHE ASP PHE SER HIS SER LEU SEQRES 12 A 215 SER ALA LEU HIS PHE SER GLU ASP GLU ILE ALA LEU TYR SEQRES 13 A 215 THR ALA LEU VAL LEU ILE ASN ALA HIS ARG PRO GLY LEU SEQRES 14 A 215 GLN GLU LYS ARG LYS VAL GLU GLN LEU GLN TYR ASN LEU SEQRES 15 A 215 GLU LEU ALA PHE HIS HIS HIS LEU CYS LYS THR HIS ARG SEQRES 16 A 215 GLN SER ILE LEU ALA LYS LEU PRO PRO LYS GLY LYS LEU SEQRES 17 A 215 ARG SER LEU CYS SER GLN HIS SEQRES 1 B 215 ALA SER LEU THR GLU ILE GLU HIS LEU VAL GLN SER VAL SEQRES 2 B 215 CYS LYS SER TYR ARG GLU THR CYS GLN LEU ARG LEU GLU SEQRES 3 B 215 ASP LEU LEU ARG GLN ARG SER ASN ILE PHE SER ARG GLU SEQRES 4 B 215 GLU VAL THR GLY TYR GLN ARG LYS SER MET TRP GLU MET SEQRES 5 B 215 TRP GLU ARG CYS ALA HIS HIS LEU THR GLU ALA ILE GLN SEQRES 6 B 215 TYR VAL VAL GLU PHE ALA LYS ARG LEU SER GLY PHE MET SEQRES 7 B 215 GLU LEU CYS GLN ASN ASP GLN ILE VAL LEU LEU LYS ALA SEQRES 8 B 215 GLY ALA MET GLU VAL VAL LEU VAL ARG MET CYS ARG ALA SEQRES 9 B 215 TYR ASN ALA ASP ASN ARG THR VAL PHE PHE GLU GLY LYS SEQRES 10 B 215 TYR GLY GLY MET GLU LEU PHE ARG ALA LEU GLY CYS SER SEQRES 11 B 215 GLU LEU ILE SER SER ILE PHE ASP PHE SER HIS SER LEU SEQRES 12 B 215 SER ALA LEU HIS PHE SER GLU ASP GLU ILE ALA LEU TYR SEQRES 13 B 215 THR ALA LEU VAL LEU ILE ASN ALA HIS ARG PRO GLY LEU SEQRES 14 B 215 GLN GLU LYS ARG LYS VAL GLU GLN LEU GLN TYR ASN LEU SEQRES 15 B 215 GLU LEU ALA PHE HIS HIS HIS LEU CYS LYS THR HIS ARG SEQRES 16 B 215 GLN SER ILE LEU ALA LYS LEU PRO PRO LYS GLY LYS LEU SEQRES 17 B 215 ARG SER LEU CYS SER GLN HIS HET MPD A 501 8 HET E3S A 502 35 HET MPD B 501 8 HET E3S B 502 35 HETNAM MPD (4S)-2-METHYL-2,4-PENTANEDIOL HETNAM E3S (1R)-N-(4-TERT-BUTYL-3-FLUOROPHENYL)-6-METHOXY-2-[(3- HETNAM 2 E3S OXO-2,3-DIHYDRO-1,2-OXAZOL-5-YL)ACETYL]-1,2,3,4- HETNAM 3 E3S TETRAHYDROISOQUINOLINE-1-CARBOXAMIDE FORMUL 3 MPD 2(C6 H14 O2) FORMUL 4 E3S 2(C26 H28 F N3 O5) FORMUL 7 HOH *18(H2 O) HELIX 1 AA1 SER A 266 GLU A 283 1 18 HELIX 2 AA2 ARG A 288 ARG A 296 1 9 HELIX 3 AA3 SER A 301 LYS A 311 1 11 HELIX 4 AA4 SER A 312 ARG A 337 1 26 HELIX 5 AA5 CYS A 345 MET A 365 1 21 HELIX 6 AA6 GLY A 384 GLY A 392 5 9 HELIX 7 AA7 CYS A 393 LEU A 410 1 18 HELIX 8 AA8 SER A 413 ILE A 426 1 14 HELIX 9 AA9 GLU A 435 THR A 457 1 23 HELIX 10 AB1 SER A 461 LEU A 466 1 6 HELIX 11 AB2 SER B 266 THR B 284 1 19 HELIX 12 AB3 ARG B 288 GLN B 295 1 8 HELIX 13 AB4 ARG B 296 ASN B 298 5 3 HELIX 14 AB5 SER B 301 LYS B 311 1 11 HELIX 15 AB6 SER B 312 ARG B 337 1 26 HELIX 16 AB7 CYS B 345 ALA B 355 1 11 HELIX 17 AB8 GLY B 356 MET B 365 1 10 HELIX 18 AB9 GLY B 384 GLY B 392 5 9 HELIX 19 AC1 CYS B 393 LEU B 410 1 18 HELIX 20 AC2 SER B 413 ILE B 426 1 14 HELIX 21 AC3 GLU B 435 THR B 457 1 23 HELIX 22 AC4 ARG B 459 LEU B 463 5 5 SHEET 1 AA1 3 TYR A 369 ASN A 370 0 SHEET 2 AA1 3 THR A 375 PHE A 378 -1 O THR A 375 N ASN A 370 SHEET 3 AA1 3 LYS A 381 GLY A 383 -1 O GLY A 383 N VAL A 376 SHEET 1 AA2 3 TYR B 369 ASN B 370 0 SHEET 2 AA2 3 THR B 375 PHE B 378 -1 O THR B 375 N ASN B 370 SHEET 3 AA2 3 LYS B 381 GLY B 383 -1 O GLY B 383 N VAL B 376 SITE 1 AC1 4 GLU A 304 TYR A 308 LYS A 311 ARG A 319 SITE 1 AC2 11 GLN A 286 CYS A 320 HIS A 323 LEU A 324 SITE 2 AC2 11 ARG A 364 MET A 365 PHE A 377 PHE A 378 SITE 3 AC2 11 GLU A 379 GLY A 380 PHE A 388 SITE 1 AC3 6 GLU B 290 GLU B 304 GLY B 307 TYR B 308 SITE 2 AC3 6 LYS B 311 ARG B 319 SITE 1 AC4 10 GLN B 286 CYS B 320 HIS B 323 LEU B 324 SITE 2 AC4 10 ARG B 364 PHE B 377 PHE B 378 GLU B 379 SITE 3 AC4 10 GLY B 380 PHE B 388 CRYST1 99.842 99.842 125.484 90.00 90.00 120.00 P 61 12 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.010016 0.005783 0.000000 0.00000 SCALE2 0.000000 0.011565 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007969 0.00000